{"filing":{"accession_number":"0001140361-26-032644","cik":"0001444192","ticker":"GRCE","company_name":"Grace Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"ef20079525_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/ef20079525_8k.htm"},"events":[{"id":27531,"run_id":25101,"accession_number":"0001140361-26-032644","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Grace Therapeutics issued a press release on August 13, 2026, announcing financial results for the three months ended June 30, 2026, including net loss of $15.8 million (vs. $3.4 million prior year), a $13.5 million impairment of IPR\u0026D for GTx-101 and GTx-102, and cash runway through end of 2028. The disclosure is furnished under Item 2.02 \"Results of Operations and Financial Condition\" with the press release attached as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.","company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29110,"accession_number":"0001140361-26-032644","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Grace Therapeutics issued a press release on August 13, 2026, announcing financial results for the three months ended June 30, 2026, including net loss of $15.8 million (vs. $3.4 million prior year), a $13.5 million impairment of IPR\u0026D for GTx-101 and GTx-102, and cash runway through end of 2028. The disclosure is furnished under Item 2.02 \"Results of Operations and Financial Condition\" with the press release attached as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:03:00.241176+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29110,"accession_number":"0001140361-26-032644","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Grace Therapeutics issued a press release on August 13, 2026, announcing financial results for the three months ended June 30, 2026, including net loss of $15.8 million (vs. $3.4 million prior year), a $13.5 million impairment of IPR\u0026D for GTx-101 and GTx-102, and cash runway through end of 2028. The disclosure is furnished under Item 2.02 \"Results of Operations and Financial Condition\" with the press release attached as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:03:00.241176+00:00","company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","filing_date":"2026-08-13"}]}